ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

Market Cap	1.22B -69.1%
Revenue (ttm)	170.32M +25.6%
Net Income	-265.74M
EPS	-0.63
Shares Out	429.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	191,800
Open	2.880
Previous Close	2.890
Day's Range	2.760 - 2.945
52-Week Range	2.715 - 9.170
Beta	0.29
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About HKG:1541

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 197
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1541

Financial Performance

In 2025, HKG:1541's revenue was 154.29 million, an increase of 108.09% compared to the previous year's 74.15 million. Losses were -218.58 million, -30.80% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 3, 2026

Data Sources Report a data error